Early detection paired with modern therapy genuinely improves survival.
In the Philippines, where lung cancer has long been a sentence handed down too late, Healthway Cancer Care Hospital and AstraZeneca have opened a Lung Center of Excellence—a dedicated space where artificial intelligence, early screening, and modern therapy converge in an effort to shift the moment of diagnosis from the end of the story to its beginning. The center arrives as PhilHealth expands coverage for low-dose CT screening, suggesting that the conditions for change, long absent, may finally be gathering. It is a reminder that mortality is not always fate; sometimes it is a failure of timing, and timing can be changed.
- Lung cancer kills more Filipino cancer patients than any other malignancy, largely because most cases are found only after the disease has already spread beyond reach.
- AI-powered chest X-ray analysis and low-dose CT scans are now being deployed to catch suspicious lesions before symptoms appear, targeting high-risk patients between 50 and 80 with significant smoking histories or occupational exposures.
- A dedicated Lung Nodule Clinic will manage patients with ambiguous imaging findings—the uncertain middle ground where early intervention can still make the difference between cure and palliation.
- The center offers the full arc of modern treatment: surgery, chemotherapy, radiation, targeted molecular therapies, and immunotherapy, addressing both the common and the more aggressive forms of the disease.
- PhilHealth's recent expansion of low-dose CT coverage signals a policy shift that could widen access beyond the private hospital setting, though awareness gaps and specialist shortages remain formidable barriers.
Healthway Cancer Care Hospital, the Philippines' only facility built entirely around cancer care, has partnered with AstraZeneca to open a Lung Center of Excellence—a unit designed to catch lung cancer early and guide patients through every stage of care. The partnership confronts a stubborn reality: Filipino patients are arriving at hospitals with advanced disease, when treatment options are few and outcomes are poor.
The center will use artificial intelligence developed by Qure.ai to analyze chest X-rays with a precision that exceeds unaided human reading, and will offer low-dose CT scans to screen high-risk populations. A separate Lung Nodule Clinic will manage patients with suspicious findings on imaging. Dr. Gerardo Cornelio, who leads the center, has set an ambitious goal: to become the Philippines' foremost institution for thoracic cancer care and to extend that model across Asia.
Once a diagnosis is confirmed, patients will have access to surgery, radiation, chemotherapy, targeted molecular therapies aimed at specific genetic mutations, and immunotherapy. The center treats both non-small cell and small cell lung cancer. Screening eligibility focuses on patients aged 50 to 80 with at least 20 pack-years of smoking history, though family history and occupational exposure to carcinogens are also considered.
The launch comes at a moment of cautious possibility. PhilHealth has recently expanded coverage for low-dose CT screening, and advances in treatment have genuinely improved survival odds when disease is caught early. Dr. Michael Agustin, who oversees the Lung Nodule Clinic, is candid about the obstacles—low public awareness, limited access to imaging, and a shortage of specialists. Whether this model can reach beyond the walls of a private hospital remains uncertain. But the center is open, and the tools it carries are real.
Healthway Cancer Care Hospital, the Philippines' only dedicated cancer treatment facility, has joined forces with AstraZeneca to open a Lung Center of Excellence—a new unit designed to catch lung cancer early, when it is still treatable, and to shepherd patients through every stage of care from screening to survival.
The partnership reflects a growing recognition that lung cancer in the Philippines is being diagnosed too late. Patients arrive at hospitals with advanced disease, when options narrow and outcomes darken. The center aims to reverse this pattern by making early detection routine rather than rare. It will operate a separate Lung Nodule Clinic for patients with suspicious spots on imaging, and it will deploy artificial intelligence to read chest X-rays with the precision that human eyes alone cannot match. The hospital is working with Qure.ai, an AI developer, to power this screening tool. Low-dose CT scans—a gentler, faster imaging method than standard CT—will also be available to identify early-stage disease in high-risk populations.
Dr. Gerardo Cornelio, who leads the Lung Center of Excellence, frames the ambition plainly: to become the leading institution in the Philippines for screening, detecting, diagnosing, and treating thoracic cancers, and to expand that footprint across Asia within the next few years. The center will treat both non-small cell lung cancer, which accounts for most cases, and small cell lung cancer, a more aggressive variant. Once diagnosis is confirmed, patients will have access to surgery, radiation, chemotherapy, targeted molecular therapies that attack specific genetic mutations, and immunotherapy—drugs that train the immune system to recognize and destroy cancer cells.
The timing of this launch matters. Lung cancer incidence is rising in the Philippines, and mortality remains stubbornly high because most patients are diagnosed after the disease has spread. Yet the calculus is changing. PhilHealth, the government health insurance program, has recently begun covering low-dose CT screening. Advances in treatment have also shifted the survival curve upward. Early detection, paired with modern therapy, now offers genuine hope of cure rather than mere postponement of decline.
Dr. Michael Agustin, who oversees the Lung Nodule Clinic, acknowledges the obstacles the country faces. Lung cancer screening is still new to the Philippines. Many patients lack awareness of their risk. Many more lack access to the imaging and specialists required to catch disease early. As the nation's first hospital built entirely around cancer care, Healthway is positioning itself to fill that gap—to create a program that is both sustainable and efficient, one that moves diagnosis from late to early, from incurable to treatable.
Eligibility for screening is not universal. The center targets patients between 50 and 80 years old with a significant smoking history—at least 20 pack-years, a measure that multiplies daily cigarette use by years of smoking. Current or recent smokers qualify. But the center will also consider other risk factors: a family history of lung cancer, or occupational exposure to asbestos, radon, or other carcinogens. The specificity matters. It focuses resources on those most likely to benefit, and it acknowledges that lung cancer is not only a smoker's disease.
What emerges from this partnership is a model for how a single hospital, working with a global pharmaceutical company and emerging technology, can begin to reshape outcomes in a disease that has long been a death sentence. The Lung Center of Excellence is not a cure. It is a tool—a way to catch cancer before it becomes unstoppable, and to treat it with weapons that did not exist a decade ago. Whether it can scale, whether it can reach beyond the walls of a private hospital to touch the broader population, remains an open question. But the center exists now, and it is ready.
Notable Quotes
The vision is to be the leading center for screening, detection, diagnosis, and treatment of thoracic malignancies in the Philippines, and to expand across Asia in the next couple of years.— Dr. Gerardo Cornelio, head of HCCH Lung Center of Excellence
Lung cancer screening is just beginning to be introduced in the Philippines. As the country's first dedicated cancer care hospital, we are committed to addressing the leading cause of death among cancer patients through early diagnosis.— Dr. Michael Agustin, head of Lung Nodule Clinic
The Hearth Conversation Another angle on the story
Why does lung cancer in the Philippines get diagnosed so late?
It's partly awareness—many people don't know they're at risk until symptoms appear. But it's also infrastructure. Screening tools like low-dose CT scans weren't widely available or covered by insurance until very recently. By the time someone feels sick enough to seek care, the cancer has often spread.
So this center is trying to flip that around?
Exactly. Instead of waiting for symptoms, they're looking for nodules on imaging in people who are likely to have disease. AI reads the X-rays faster and catches things a radiologist might miss. It's preventive rather than reactive.
Who can actually access this? Is it only for wealthy patients?
The eligibility criteria are specific—age 50 to 80, significant smoking history, current or recent smokers. But it's still a private hospital. The real question is whether PhilHealth's recent coverage expansion will make this available to more people, or whether it remains out of reach for most.
What makes this partnership with AstraZeneca important?
AstraZeneca brings expertise in lung cancer drugs—immunotherapies, targeted therapies—and the resources to help build a center of excellence. It's not charity; they benefit from having a flagship facility in Asia. But the partnership does mean the hospital has access to cutting-edge treatment options that might not otherwise be available here.
Is this actually going to change outcomes?
If it works as intended, yes. Early detection paired with modern therapy genuinely improves survival. The challenge is scale. One hospital in Manila can't treat all of the Philippines. But it can be a model, a proof of concept that early detection is possible and worth doing.